, Tracking Stock Market Picks
Enter Symbol:
Rating: GHDX

Genomic Health, Inc. (NASDAQ: GHDX) downgraded to Neutral by Credit Suisse

Friday,  Feb 7, 2014  8:25 AM ET by Betsy O'Brien Harrison

Credit Suisse downgraded Genomic Health, Inc. (NASDAQ: GHDX) to Neutral.
Previously Credit Suisse downgraded to Genomic Health, Inc. (NASDAQ: GHDX) to Outperform on 09/25/2012, when the stock price was $34.85.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy